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Abstract
Uroplakin Ib is a structural protein on the surface of
urothelial cells. Levels of uroplakin Ib mRNA are dra-
matically reduced or absent in many transitional cell
carcinomas, but the molecular mechanisms responsi-
ble remain undetermined. Previously, we showed that
loss of uroplakin Ib expression correlated with CpG
methylation of Sp1/NFKB–binding motifs within the
proximal promoter. In this study, we show that reporter
activity was completely blocked by the methylation of
three CpG pairs in this promoter region. Gel shift analy-
sis using purified proteins or nuclear extracts showed
that Sp1 and NFKB bound to motifs encompassing
two of the three CpG pairs. Interestingly, themethylation
of these two CpG sites did not prevent the binding of
proteins to the promoter in gel shift analyses. Addition-
ally, mutation of these two CpGs did not affect reporter
activity, but mutation of 6-bp fragment spanning each
CpG partially inhibited reporter activity, suggesting that
these sites were functional. A requirement for both Sp1
and NFKB in regulating reporter activity was confirmed
in transfection experiments using plasmids expressing
individual proteins. Our data suggest that the methyl-
ation of specific CpG sites can silence the uroplakin Ib
promoter, at least in part, by blocking the binding of Sp1
and NFKB, although other factors may be involved.
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Introduction
Uroplakin Ib belongs to the tetraspanin family of membrane
proteins [1–3] and forms plaque complexes with uroplakins
Ia, II, and III along the asymmetric unit membrane of um-
brella cells of themammalian urothelium [4–6]. Formation of
these plaques by specific interactions between the four
uroplakins provides the luminal surface of the bladder with
strength and flexibility, as well as an impermeable barrier
to prevent urine invasion of underlying tissues. Uroplakin Ib
is also required for the export of uroplakin III from the Golgi
apparatus to form mature plaques on the apical surface
of urothelial cells [7]. Because complexes of uroplakins Ib
and III are essential for assembly of plaques on the mature
fully differentiated urothelium, these data support the hypothe-
sis that uroplakin Ib has a key functional role in driving the final
stages of urothelial differentiation. Although initially considered
to be entirely urothelium-specific, recent reports have sug-
gested that uroplakin Ib mRNA is also expressed in the cornea
and conjunctival epithelium [8], trachea, placenta, pancreas, and
kidney [9] (UniGene Hs.2715 Bladder, Brain, Eye, Kidney, Lung,
Muscle, Ovary, Pancreas, Placenta, Soft Tissue, Stomach,
Tongue, and Uterus). However, given that a definitive biologic
function for uroplakin Ib is yet to be determined, the importance
of these observations is not clear.
Other tetraspanin proteins, including CD63, Co-029, and the
leukocyte antigens CD9, CD53, CD37, CD82/KAI1, and Tapa-1,
have been implicated in the growth regulation and activation of a
wide range of cells, and it has been suggested that they
represent a family of signal transduction molecules and adhe-
sion- or motility-related receptors. Recent data have also
stressed the importance of interactions between tetraspanin
proteins and integrins for adhesion and signal transduction
(reviewed in Refs. [10,11]). At least four tetraspanins (CD82/
KAI1, KITENIN, CD63, and CD9) have roles in tumor progres-
sion. Loss of KAI1 expression is strongly correlated with ad-
vanced disease in many different cancer types, including
bladder cancer [12], recurrence following initial treatment [13],
and poor outcome [14]. Experimental studies have shown that
overexpression of KAI1/CD82 in KAI1-negative colon, breast,
and prostate cancer cell lines alters cell–cell and cell–matrix
adhesion, and suppresses in vitro invasiveness and in vivo
metastasis [15–17]. Similar results have been obtained for CD9
[18], and overexpression of CD63 in CD63-negative melanoma
cells inhibited the growth andmetastasis of transplanted tumors
in nude mice [19], although more recent data have suggested
that interpretation of data concerning the suppressive effect
of CD63 may need to be treated with caution [20]. However,
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molecular mechanisms leading to loss of tetraspanin expres-
sion in advanced cancer remain largely uncharacterized.
In a recent study [21], we provided evidence that methyla-
tion of a CpG island spanning the proximal promoter of the
human uroplakin Ib gene was closely correlated with lack of
uroplakin Ib mRNA expression in both clinical samples of tran-
sitional cell carcinoma (TCC) of the bladder and in TCC cell
lines. Reactivation of uroplakin Ib mRNA expression in uro-
plakin Ib–negative TCC cell lines by 5-aza-2V-deoxycytidine
further supported a regulatory role for methylation in gene
transcription. Our preliminary data also indicated that loss of
uroplakin Ib expression was correlated with methylation of
CpG residues located within specific Sp1/NFnB– and Sp1-
binding motifs in the core uroplakin Ib promoter, suggesting
that thesemotifs playeda key role in regulating transcription. In
the current study, we further explored the importance of these
binding motifs to the expression of the uroplakin Ib gene, and
we have shown that Sp1 and NFnB were key determinants
of uroplakin Ib transcription. Our data provide additional evi-
dence that methylation of specific CpG residues silenced the
uroplakin Ib gene during bladder cancer progression.
Materials and Methods
Cell Lines
The TCCSuP, J82, and T24 cell lines derived from TCCs
and the colorectal carcinoma cell line SW480 were all ob-
tained from ATCC (Rockville, MD). The colorectal carcinoma
cell line LIM1215 was kindly supplied by Dr. R. Whitehead
(Ludwig Institute for Cancer Research, Melbourne, Victoria,
Australia). Dr. D. Leavesley (Royal Adelaide Hospital, Ade-
laide, South Australia, Australia) kindly provided the 5637 cell
line. The HT1376, VM-Cub1, and VM-Cub3 cell lines were
provided by Dr. Marc-Oliver Grimm (Department of Urology,
Heinrich-Heine University, Dusseldorf, Germany). RT112
cells were obtained from Professor Pamela Russell (Oncol-
ogy Research Centre, Prince of Wales Hospital, Sydney,
Australia). Breast cancer cell lines (MDA-MB-231, MCF7,
and MCF10A) were obtained from Dr. Sally Stephenson
(Department of Haematology–Oncology, The Queen Eliza-
beth Hospital, Woodville, South Australia, Australia). Cell lines
were maintained in Dulbecco’s modified Eagle’s medium
(DMEM; pH 7.4) supplemented with 10% fetal calf serum at
37jC in an atmosphere of 5% CO2.
Expression of Uroplakin Ib mRNA by Semiquantitative
Reverse Transcription–Polymerase Chain Reaction
(RT-PCR)
RNA was isolated from cell lines using Trizol Reagent
(Invitrogen, Carlsbad, CA), according to the manufacturer’s
instructions. RT-PCR amplification of a 741-bp uroplakin Ib
cDNA product was carried out as previously described [21].
To verify RNA quality and to ensure equal loading of cDNA
into the reactions, levels of GAPDH were also analyzed.
GAPDH was not amplified from the RNA template in the
absence of reverse transcriptase (data not shown), demon-
strating that neither genomic sequence nor the GAPDH
pseudogene was amplified under these PCR conditions.
Reaction products were separated on a 1.5% agarose gel
at 100 V and then viewed using ethidium bromide.
Electromobility Shift Assay (EMSA)
Nuclear extracts from HT1376, RT112, and SW1710 cells
were prepared by the Pierce NE-Per system (Pierce Endo-
gen, Rockford, IL), as described by themanufacturer. Protein
concentrationswere determined byBCAassay (PierceEndo-
gen) before extracts were aliquoted and stored at 80jC.
Single-stranded, complementary 25-mer oligonucleotides
encompassing Sp1/NFnB–binding motifs and including
CpG3 and CpG4 within the uroplakin Ib promoter [21] (see
Figure 1A and Table 1), and oligonucleotides containing
consensus-binding motifs for Sp1 and NFnBwere purchased
from Sigma-Aldrich (Castle Hill, New South Wales, Australia).
Oligonucleotides containing 5-Me cytosine at CpG3 and/or
CpG4werepurchased fromGeneworks (Adelaide,SouthAus-
tralia, Australia). All complementary oligonucleotides were an-
nealed to form double-stranded probes. A double-stranded
oligonucleotide containing a consensus AP1-binding motif
was obtained from Santa Cruz Biotechnology (Santa Cruz,
CA). Radioactive probes were generated by labeling a single-
stranded promoter oligonucleotide with T4 polynucleotide
kinase (New England Biolabs, Beverly, MA) and [g32P]dATP
(Geneworks), annealing the complementary oligonucleotide,
and purifying through a Sephadex G25 Quickspin column
(Roche Applied Science, Indianapolis, IN). Binding assays
were performed for 10 minutes on ice using 6 ml of nuclear
extract (6–10 mg of total protein, except for HT1376, which is
20 mg) in 30-ml reactions containing a binding buffer (10 mM
HEPES, pH 7.8, 50 mM KCl, 5 mM MgCl2, 1 mM EDTA, and
5% glycerol), 1 mM DTT, 0.25 mg of poly[dI:dC], and 0.2 ml of
32P-labeled probe (13 fmol; >30,000 cpm/ml). In competition
experiments, a cold competitor (100 molar excess) was
includedwith the nuclear extract for 10minutes prior to addition
of labeled probe. All gels were dried and examined by Phos-
phoimage analysis.
In experiments using purified transcription factors, recom-
binant human Sp1 and human NFnB (p50) were obtained
from Promega (Madison, WI). In each experiment, 900 ng of
Sp1 or 2.2 ml of p50 was used. Reactions were performed as
described above, except that competitors were used at100
to 300 molar excess.
Cloning of the Uroplakin Ib Reporter Construct
A 246-bp fragment (Figure 1A;152 to +94) [22] spanning
the uroplakin Ib proximal promoter and exon 1was cloned into
the pGL3-Basic reporter plasmid (Promega), which contained
a firefly luciferase reporter gene (Figure 1B). This fragment
of the uroplakin Ib promoter has previously been shown to be
sufficient for the transcription of a reporter gene [22].
The uroplakin Ib promoter fragment was amplified from
50 ng of genomic DNA isolated from the peripheral blood of
a normal volunteer, using 0.5 mM of each primer (sequences
are given in Table 2), 2mMMgCl2, 200 mMdNTPs, and 1.25U
ofHigh-FidelityPfuUltraTaqPolymerase (Stratagene, LaJolla,
CA) in a total volume of 50 ml. Amplification was achieved in
1092 Methylation Regulates Uroplakin lb Transcription Cowled et al.
Neoplasia . Vol. 7, No. 12, 2005
an Eppendorf Mastercycler using the following protocol: 94jC
for 5 minutes; then 34 cycles of 94jC for 1 minute, 61jC for
1 minute, and 72jC for 3 minutes; followed by a final exten-
sion of 72jC for 5 minutes.
PCR DNA product was electrophoresed through a low-
melting-point agarose gel, excised, and then purified using
a Qiaquick gel extraction kit (Qiagen, Clifton Hills, Victoria,
Australia), according to the manufacturer’s instructions. The
purified fragment was then TA-cloned into the plasmid vec-
tor pGEM-T Easy (Promega). Because the restriction en-
zyme recognition sites in pGEM-T Easy were not compatible
with those in the multiple cloning site in pGL3-Basic, the pro-
moter fragment was first subcloned into pBlueScript II KS(+)
(Stratagene) to introduce appropriate restriction sites for the
Figure 1. Structure and functional features of the proximal promoter region and exon 1 of the uroplakin Ib gene. (A) The CpG pairs are marked in bold type and
numbered 2 to 11, with the numbering shown below the sequence [21]. The Ts in bold and larger type represent the beginning and end of the primer sequences
used to amplify and clone the promoter fragment for subsequent cloning in the reporter vectors and thus define the fragment of the promoter and exon 1 examined
in these studies. The sequence in italics defines the location of the oligonucleotides used in EMSA experiments. Exon 1, as defined in Ref. [22], is boxed. The
underlined sequences represent core sequences for putative transcription factor –binding sites, as determined by transcription factor prediction programs TESS
and MatInspector [21]. A potential CCAAT box is also marked. The locations of restriction sites used to excise fragments for in vitro methylation and cloning are
also marked. (B) Diagram of the uroplakin Ib pGL3-Basic construct used for luciferase reporter assays. (C) Structure of the promoter insert cloned into pGL3-Basic
for reporter assays. PBS represents short sequences derived from pBlueScript II KS(+). The locations of restriction sites used to excise fragments for in vitro
methylation and cloning are marked.
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final step of the cloning. The fragment was excised from
pGEM-T Easy by EcoRI (New England Biolabs) digestion
then cloned into pBlueScript II KS(+) at the EcoRI site before
being excised from this construct using KpnI and SacI. This
fragment was finally cloned into SacI/KpnI–digested pGL3-
Basic (Figure 1C ). Correct insertion of the promoter fragment
into the reporter and verification of the correct promoter se-
quence were ensured by direct sequencing; its structure is
shown in Figure 1B.
Transient Transfections
Transfections were performed using Lipofectamine 2000
reagent (Invitrogen), according to the manufacturer’s in-
structions. To control for transfection efficiency, the pSV2CAT
plasmid, which constitutively expresses high levels of chlor-
amphenicol acetyl transferase (CAT), was cotransfected into
cells with a reporter construct. Briefly, 4 mg of total plasmid
was diluted into 250 ml of DMEM; 5 ml of Lipofectamine 2000
reagent diluted in 250 ml of DMEM was added; and the
mixture incubated for 20 minutes. The transfection mixture
was then added to the wells of a six-well plate containing
nearly confluent cells and then incubated for 24 hours.
Protein lysates were prepared using a lysis buffer from the
CAT ELISA kit (Roche Applied Sciences), according to the
manufacturer’s instructions. Analysis of luciferase and CAT
activity was performed as described below.
Luciferase and CAT Reporter Assays
Cells were lysed and uroplakin Ib promoter activity was
assessed using the Luciferase assay system (Promega). Cell
lysate (50 ml) was assayed and luminescence was measured
in an AutoLumat Plus LB 953 Luminometer (Berthold Tech-
nologies, Bad Wildbad, Germany). The results were normal-
ized to protein concentration, asmeasured byBradford assay
using Protein Assay Reagent (BioRad, Hercules, CA).
CAT activity in cell lysates was assayed by ELISA using
a CAT ELISA kit (Roche Molecular Biochemicals), accord-
ing to the manufacturer’s instructions. The absorbance was
measured at 405 nm using a Microplate reader (model
680; BioRad).
In Vitro Methylation of Uroplakin Ib Promoter Sequences
Using Sss1 Methylase
The uroplakin Ib promoter fragment was excised from
within the pGL3-Basic/uroplakin Ib reporter construct by SacI
and KpnI digestion, purified, and then treated with Sss1meth-
ylase (2 U enzyme/10 mg DNA) to methylate all 10 CpG sites.
To confirm methylation, an aliquot of the methylated promoter
fragment was incubated with the methylation-sensitive restric-
tion enzyme HpaII (New England Biolabs), which cleaves the
fragment into two, only if the CpG sites are unmethylated (the
location of the HpaII site is shown in Figure 1A).
The fully methylated uroplakin Ib promoter fragment was
then added to the KpnI/SacI– linearized pGL3-Basic plasmid
and religated by overnight incubation with T4 DNA ligase.
The ligation mixture was then transfected directly into RT112
and HT1376 cells (which both express endogenous uropla-
kin Ib mRNA) and T24 and VMCub3 cells (which lack
uroplakin Ib expression), along with pSV2CAT. Luciferase
and CAT activities were then assayed 24 hours after trans-
fection. To control for possible bias introduced by the cloning
process on transcriptional activation, a promoter fragment
was processed in parallel with the methylated promoter
fragment above, with the single exception that Sss1 methyl-
ase was omitted. This fragment was then ligated into pGL3-
Basic and transfected as above.
Table 2. Sequences of PCR Primers.
Uroplakin Ib RT-PCR TGTTCGTTGCTTCCAGGGCCTGC AGTAGAACATGGTACCCAGGAGAACC
GAPDH control CCACCCATGGCAAATTCCATGGCA TCTAGACGCAGGTCAGGTCCACC
Cloning of uroplakin Ib promoter fragment TGTCAGAGTCACACATTCCAAAG ACTCACAGCGCCTCCTCTTTC
Plasmid-specific primers for sequencing and PCR CTAGCAAAATAGGCTGTCCCC CTTTATGTTTTTGGCGTCTTCCA
Mutagenesis cloning
Plasmid-specific primers CTAGCAAAATAGGCTGTCCCCAGTGCAAGTGCAGG
CTTTATGTTTTTGGCGTCTTCCATGGTGGCTTTAC
(a) CG to TA
CpG2
GAAATCAACTGACAGCCTCTAGTTACTCCCCTACCTCAGC
CGCTGAGGATGGGGAGTAATAGGAGGCTGTCA
CpG3 and CpG4 CCTCCGGTTACTCCCCTACCTCAGTAAGGCAGGGCAGGCAGCG
CGCTGCCTGCCCTGCCTTACTGAGGTAGGGGAGTAACCGGAGG
(b) 6-bp mutations
CpG3
CCTCCGGTTACTCCTTTATTTCAGCGAGGCAGGGCAGGCAGCG
CGCTGCCTGCCCTGCCTCGCTGAAATAAAGGAGTAACCGGAGG
CpG4 CCTCCGGTTACTCCCCCGCCTCTTTATTGCAGGGCAGGCAGCG
CGCTGCCTGCCCTGCAATAAAGAGGCGGGGGAGTAACCGGAGG
The underlined sequences represent the mutated sequences, and the residues in bold mark the location of CGs.
Table 1. Oligonucleotide Sequences Used for EMSA Experiments.
Wild-type uroplakin
Ib promoter
TTACTCCCCCGCCTCAGCGAGGCAG
Mutation 1 TTACTCCCCTTCCTCAGCGAGGCAG
Mutation 2 TTACTCCCCCGCCTCAGTTAGGCAG
Mutation 3 TTACTCCCCTTCCTCAGTTAGGCAG
5Me-CpG3 TTACTCCCC(5-Me)CGCCTCAGCGAGGCAG
5Me-CpG4 TTACTCCCCCGCCTCAG(5-Me)CGAGGCAG
5Me-CpG3 and
5Me-CpG4
TTACTCCCC(5-Me)CGCCTCAG(5-Me)CGAGGCAG
The 5V–3V sequences are shown. CpG residues 3 and 4, respectively, are
underlined, and mutated residues are in bold.
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To determine if methylation of CpG3 and CpG4 specifically
played a role in regulating the transcription of the uroplakin Ib
promoter, a smaller 61-bp fragment of the promoter spanning
both these sites (as well as CpG5) was excised from the
uroplakin Ib KpnI/SacI promoter fragment by digesting with
Bsr I and BanI restriction enzymes (locations of the restriction
sites are shown in Figure 1A). The BsrI recognition site was
first created by site-directed mutagenesis at CpG2 in the
normal promoter sequence, which changed the second C to
A, thereby introducing the required BsrI site (Figure 1A). This
61-bp fragment was then methylated in vitro with Sss1
methylase as above and religated firstly with the other two
promoter fragments and then into pGL3-Basic, linearized with
SacI and KpnI. The ligation mixture was then transfected
directly into cell lines as above. A control nonmethylated re-
porter construct was also prepared exactly as described
above, but with the omission of Sss1 methylase.
Site-Directed Mutagenesis
To ascertain the functional importance of Sp1- and NFnB-
binding siteswithin the 246-bp uroplakin Ib promoter fragment,
the sequence was mutated at CpG3 and CpG4, which span
the consensus-binding sites for these transcription factors.
These sites were mutated either individually or together, using
a PCR-based site-directedmutagenesis approach. The pGL3-
Basic/uroplakin Ib construct was used as a template in PCRs
using primers carrying the desired mutation, thus inactivating
the Sp1- and/or NFnB-binding site. Mutagenesis reactions
were carried out to introduce either the short (CG to TA) or
the longer (six basesaround theCpGsite)mutation.Sequences
of primers are given in Table 2 and show the location of mutated
bases. PCR conditions included 15 mM MgCl2 and primer
concentrations of 2 ng/ml. Amplification was achieved with the
proofreading Taq Polymerase PfuTurbo (Stratagene) and with
conditions of 95jC for 15 minutes, followed by 30 cycles of
96jC for 1 minute, 60jC for 1 minute, and 72jC for 1 minute,
with a final extension of 72jC for 7 minutes. Three reactions
were performed to obtain the full-length mutated product, with
the first PCR amplifying the sequence upstream to the muta-
tion and with a second reaction amplifying the sequence
downstream of the mutation. A final PCR was then carried
out using outer primers only and the products of the two pre-
vious reactions as templates. After amplification, the product
was digested with SacI and KpnI and electrophoresed through
low-melting-point agarose; thebandof appropriate size (251bp)
was excised and purified using the Qiaquick gel purification kit
(Qiagen), before religation into SacI/KpnI–digested pGL3-
Basic plasmid. Direct sequencing was performed to confirm
the successful introduction of desired mutations.
Results
Transcriptional Activity of the Uroplakin Ib Reporter
Construct in Bladder Cancer and Non-bladder Cell Lines
We have previously reported that methylation of the
uroplakin Ib promoter in TCC cell lines and in clinical samples
of TCC is associatedwith silencing of uroplakin Ib expression,
and that this silencing correlates with the methylation of two
specific CpG residues (CpG3 and CpG4) within the proximal
region of the uroplakin Ib promoter [21] (Figure 1A). To obtain
more direct evidence for the importance of proximal promoter
methylation in the control of uroplakin Ib expression, we ini-
tially generated a reporter plasmid (pGL-Basic/uroplakin Ib)
containing a 241-bp fragment (residues 152 to +94, includ-
ingCpG3andCpG4) spanning theproximal promoter, exon1,
and part of intron 1 (Figure 1, A–C). A similar-sized fragment
of the uroplakin Ib promoter has previously been shown to
support transcription in a variety of cell types after transient
transfection [22]. Our uroplakin Ib reporter construct was
transfected into several bladder cancer cell lines, which we
have previously shown [21] to normally express clearly detect-
able uroplakin Ib mRNA (RT112 and HT1376; mRNA levels
in RT112 >HT1376) or which do not have detectable uroplakin
IbmRNA (T24, J82, VMCub3, 5637, and TCCSup) andwhose
levels of uroplakin Ib mRNA reflected the methylation status
of the uroplakin promoter (summarized in Figure 2A). Trans-
fection results presented in Figure 2A clearly show that uro-
plakin Ib reporter activity reflected endogenous uroplakin Ib
expression. Reporter activities were highest in RT112 and
HT1376, with activity in RT112 that is almost five-fold higher
than in HT1376. Reporter activities in cell lines that do not
normally express detectable uroplakin Ib mRNA were at least
four-fold lower than in HT1376, suggesting that this 241-bp
promoter fragment contains sequences important for the
determination of endogenous uroplakin Ib mRNA levels. This
was confirmed by examining reporter activity in a series of non-
urothelial cell lines (Figure 2B). These cell lines did not express
endogenous uroplakin Ib mRNA (summarized in Figure 2B)
and induced only very low levels of luciferase activity (2- to 10-
fold lower than in HT1376; Figure 2B).
In Vitro Methylation of the Uroplakin Ib Promoter
Silences Transcription
To assess the effects of methylation on the activity of the
uroplakin Ib reporter, in preliminary experiments, the entire
pGL3-Basic/uroplakin Ib reporter plasmid was methylated
in vitro with Sss1 methylase and then transfected into
RT112, HT1376, or T24 cells. Although methylation by this
method completely silenced luciferase activity, a similar result
was obtained using a methylated pGL3-Control vector, which
constitutively expressed luciferase from an SV40 promoter
(data not shown), suggesting that methylation of nonspecific
CpG sites within the plasmid itself was affecting transcrip-
tional activity. To overcome this problem, an alternative ap-
proach was used [23], whereby the 241-bp uroplakin Ib
promoter fragment was excised from pGL3-Basic/uroplakin
Ib by SacI and KpnI digestion, and then methylated in vitro
using Sss1 methylase. This reaction resulted in the methyl-
ation of only the 10 CpG pairs within the promoter fragment.
This methylated promoter was then incubated with SacI/
KpnI – linearized pGL3-Basic/uroplakin Ib and T4 ligase,
and the entire ligation mixture was transfected directly into
cell lines described above. As control, cells were also trans-
fected with a ligation mixture containing an unmethylated
promoter fragment that was prepared in parallel, but without
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Sss1methylase treatment. All cells were harvested 24 hours
after transfection and luciferase activity was determined.
Results summarized in Figure 3A clearly show that methyl-
ation of the promoter fragment dramatically inhibited lucifer-
ase reporter activity by >99% in RT112 cells and by 97% in
HT1376 cells. In addition, the very low level of reporter activity
obtained from T24 cells was also inhibited by approximately
92% following promoter methylation.
To more directly assess the importance of specific CpG
residues, a short 61-bp fragment encompassing CpG3 to
CpG5 (Figure 1A) was methylated in vitro, religated into
pGL3-Basic/uroplakin Ib, and transfected into cells, as de-
scribed above. Results presented in Figure 3B show that
methylation of the promoter fragment containing only three
CpG sites was as effective as methylation of the full pro-
moter fragment in inhibiting luciferase activity in RT112
and HT1376 cells. However, in contrast to the inhibition
of reporter activity observed when the complete promoter
was methylated, there was little effect on very low levels
of reporter activity in T24 cells. Taken together, these data
suggested that CpG3, CpG4, and CpG5 are important for
methylation-mediated silencing of high levels of transcription
and provided experimental support to our previous study,
which indicated the importance of CpG3 and CpG4 in regu-
lating transcription [21].
Transcription Factor Binding to the Core Region of the
Uroplakin Ib Promoter
Because methylation of CpG pairs 3, 4, and 5 correlated
with loss of endogenous uroplakin Ib mRNA expression [21]
and because in vitro methylation of CpG3, CpG4, and CpG5
similarly inhibited activity from the uroplakin Ib promoter in a
transient transfection assay system, we investigated which
transcription factors might have binding sites affected by
Figure 2. Luciferase activity in a range of cell lines demonstrating a close correlation between levels of transcriptional activity and expression of uroplakin Ib mRNA.
Luciferase reporter activity was normalized against the expression of CAT and total protein, as determined by Bradford assay. Results are expressed as means of
three independent experiments ± SEM. (A) Uroplakin Ib reporter activity was assayed in seven TCC lines correlated with endogenous expression of uroplakin Ib, as
determined by qualitative RT-PCR. The endogenous methylation status of CpG3 and CpG4, as reported in our previous study [21], also correlated with the
expression of uroplakin Ib mRNA and high levels of reporter activity. (B) Urothelial specificity of the expression of the uroplakin Ib reporter construct in TCC lines
RT112 and HT1376 and in five non-urothelial cancer cell lines. The highest levels of expression were detected in the urothelial cells, and all other cell lines showed
minimal reporter activity. The methylation status of CpG3 and CpG4 in cell lines HT1376 and NIH3T3 [21] is also shown. ND, not determined.
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methylation of these CpG residues. The region of the uro-
plakin Ib promoter chosen for initial examination contains
potential binding motifs for Sp1 and NFnB (Figure 1A) that
surround CpG3 and CpG4. A potential binding motif for AP4
encompasses CpG5, but this sequence is not present in the
oligonucleotide probe under analysis. Gel shift analysis with
a radiolabeled oligonucleotide probe encompassing pro-
moter residues 150 to 126 (Table 1) was used to first ex-
amine if purified recombinant human Sp1 and NFnB (p50)
were capable of binding. Several complexes formed with
rhSp1 (Figure 4A, lane 2), and specificity was confirmed by
competition with an excess cold consensus Sp1-binding
motif, but not by a consensus AP1-binding motif (Figure 4A,
lanes 3–5). A single shifted band was observed using rp50
(Figure 4B, lane 2). Interestingly, formation of this complex
was only weakly competed by a 300 molar excess cold
competitor (Figure 4B, lane 3), consistent with technical
comments from the manufacturer’s instruction manual (Pro-
mega Technical Bulletin TB110). However, there was full
competition by a consensus p50-binding motif and no com-
petition by an AP1 motif (Figure 4B, lanes 4 and 5 ). These
data suggested that Sp1 and NFnB (p50) were capable of
binding a region of the uroplakin Ib promoter encompassing
CpG pairs 3 and 4. To verify that the CpG sites bound rele-
vant transcription factors, EMSA was also carried out using
rhSp1 and rhp50 and with oligonucleotides containing muta-
tions at the CpG sites (sequences in Table 1). However, muta-
tion of the CpGs did not affect factor binding (data not shown).
To examine complexes formed in cells, nuclear extracts
from HT1376 and RT112 were analyzed because they both
expressed high levels of endogenous uroplakin Ib mRNA.
Three major complexes (A, B, and C) were detected in
HT1376 extract (Figure 5A, lane 2). Formation of all com-
plexes was dramatically reduced by competition with excess
unlabeled probe (Figure 5A, lane 3). The involvement of Sp1
and NFnB was tested by competition with an excess of
unlabeled oligonucleotide carrying consensus-binding motifs
for either factor or a consensus motif for AP1. All complexes
strongly competed with the consensus Sp1motif, but not with
the consensus AP1 motif (Figure 5A, lanes 4 and 6). In con-
trast, the consensus NFnB motif had no effect on any of the
complexes (Figure 5A, lane 5 ). In RT112 extracts, two major
Figure 3. In vitro promoter methylation silences transcriptional activity of the uroplakin Ib construct. (A) All 10 CpG sites in the uroplakin Ib promoter fragment were
methylated in vitro using Sss1 methylase before ligation into pGL3-Basic. Luciferase reporter activity was almost completely abolished in all cell lines following
transient transfection with the methylated construct. (B) A short fragment of the uroplakin Ib promoter containing only CpG3, CpG4, and CpG5 was methylated
in vitro. Luciferase reporter activity was similarly inhibited in cells following transfection with the methylated construct.
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complexes (D and E) were present (Figure 5B, lane 2), the
formation of which was dramatically inhibited by competition
with unlabeled oligo (Figure 5B, lane 3). Interestingly, con-
sensus Sp1 and NFnB motifs each completely blocked the
formation of the uppermost complex (complex D; Figure 5B,
lanes 4 and 5 ), suggesting that both Sp1 and NFnB were
required for the formation of this complex. However, these
two proteins had no effect on the lower complex (complex E),
suggesting that another unidentified protein was also capable
of binding this region of the uroplakin Ib promoter. Again,
there was no competition for complex formation with the AP1
consensus motif (Figure 5B, lane 6). These data suggested
that in cells expressing high levels of endogenous uroplakin
Ib mRNA, at least two possible scenarios might exist. In cells
exemplified by HT1376, only Sp1 bound this promoter se-
quence; however, in cells exemplified by RT112, Sp1, NFnB,
and an unidentified protein were all binding. Moreover, our
data suggested cooperative binding by Sp1 and NFnB. This
raised the possibility that the higher levels of endogenous
uroplakin Ib mRNA and uroplakin Ib reporter activity in RT112
vs HT1376 might reflect a cooperative effect of binding by
both Sp1 and NFnB—together with the presence of a third
protein—to this region of the uroplakin Ib promoter.
If methylation of CpG3 and CpG4 prevented the binding
of transcription factors to the promoter and was a key factor
in determining levels of uroplakin Ib mRNA, we reason that
these factors might still be capable of binding our uroplakin Ib
promoter probe even in cells in which endogenous uroplakin
Ib mRNA levels are very low due to methylation of the en-
dogenous promoter because these transcription factors
might still be present. To test this possibility, we performed
gel shift analysis using nuclear extracts from SW1710 cells,
which do not express detectable levels of uroplakin Ib mRNA
and in which the region of the endogenous uroplakin Ib pro-
moter is methylated [21]. In this case, two complexes were
formed (Figure 5C ), and competition experiments generated
results similar to those obtained in RT112 cells, suggesting
that Sp1, NFnB, and the unidentified protein were binding the
uroplakin Ib promoter sequence.
Because the role of CpG methylation in regulating tran-
scriptional activity was clearly demonstrated in the reporter
experiments described above, we then examined the effect
of CpG methylation on transcription factor binding to the core
region of the uroplakin Ib promoter. Oligonucleotides were
synthesized with 5-methyl cytosine incorporated at either
CpG3, CpG4, or both sites. Methylated oligos were used at
100 molar excess to compete with the binding of nuclear
extracts to the 32P-labeled wild-type oligo probe. Figure 5D–F
shows results and demonstrate that the methylated oligos
were able to compete effectively to prevent the binding of
complexes to the uroplakin Ib promoter. This result suggests
that, in contrast to the highly inhibitory effect of methylation
on reporter activity, methylation of CpG3 and CpG4 did not
inhibit the binding of complexes to the promoter.
Site-Directed Mutagenesis (CG to TA) of CpG2, CpG3,
and CpG4 Does Not Affect Uroplakin Ib Reporter Activity
Because methylation of CpG3 and/or CpG4 silenced re-
porter activity and formed part of the bindingmotifs for Sp1 and
NFnB,we initially changed bothCGpairs to TA by site-directed
Figure 4. Binding of Sp1 and the NFjB subunit p50 to the uroplakin Ib promoter. (A) Binding of rhSp1 to the uroplakin Ib oligonucleotide. Three bands, indicated by
arrows, were identified. (B) Binding of rp50 to the uroplakin Ib oligonucleotide, with one specific band indicated by an arrow.
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Figure 5. Binding of TCC nuclear extracts to the uroplakin Ib promoter. (A–C) Gel shift analysis of nuclear extracts from HT1376, RT112, and SW1710 cells using
a 32P-labeled uroplakin Ib oligonucleotide and indicated probes and competitors. Specific bands are indicated with arrows. (D–F) Gel shift analysis of nuclear
extracts from HT1376, RT112, and SW1710 cells, respectively, using a 32P-labeled uroplakin Ib oligonucleotide with competitor probes methylated at CpG3, CpG4,
or both CpG3 and CpG4.
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mutagenesis. As negative control, we also mutated CpG2 to
TAbecausemethylationof this site did not correlatewith loss of
endogenous uroplakin Ib mRNA [21]. As anticipated, mutation
of CpG2 had no effect on the activity of the reporter after
transfection into RT112 and T24 cells (Figure 6A). However,
we were surprised to discover that the activities of reporters in
which CpG3 and CpG4 were mutated to TA were also unaf-
fected (Figure 6B). One possible explanation for these data
is that methylation of CpG3 and CpG4 generates a steric
block to the binding of Sp1 and NFnB, which is not achieved
by the simple mutation of CG to TA (which still permits the
binding of these factors). In an alternative strategy, a 6-bp frag-
ment flanking either CpG3 or CpG4 was mutated (sequences
are shown in Table 2) to ensure that the Sp1- and NFnB-
binding motifs were completely disrupted. Data presented in
Figure 7 show that mutation of either CpG3 or CpG4 each
causedan almost 30% reduction in luciferase activity, suggest-
ing that each motif contributed to transcriptional activity.
Cotransfection of Expression Plasmids for Sp1 and
NFnB Family Members and the Uroplakin Ib Reporter
The data described above illustrate that rhSp1 and rhp50
can each bind to the uroplakin Ib oligonucleotide probe and
that disruption of the relevant CpG sites by methylation or
mutagenesis inhibited transcriptional activity of the reporter
construct. Cotransfection experiments were then carried out
to verify a functional role for Sp1 and NFnB in reporter
activities. Cell lines were cotransfected with combinations
of the uroplakin Ib reporter construct and plasmids express-
ing Sp1, NFnB family proteins (p50, p65, and c-Rel), and
luciferase activity, determined as above.
Results illustrated in Figure 8A show that, in RT112 cells,
cotransfection of Sp1 alone with the uroplakin Ib reporter
caused a small but consistent two-fold enhancement of
luciferase activity, whereas cotransfection of NFnB mem-
bers (p50 alone, p50 and p65, or p50 and p65 with c-Rel) had
little effect on reporter activity. However, when Sp1 was in-
cluded in cotransfections with p50, p65, or c-Rel, there was
marked enhancement of uroplakin Ib reporter activity. The
highest levels of luciferase activity (6.0 basal reporter ac-
tivity) were observed when cells were cotransfected with the
uroplakin Ib reporter and Sp1 plus p65 plus c-Rel. These
data suggested that a combination of Sp1 and NFnB might
be required for the highest levels of activity from the uropla-
kin Ib promoter. We extended our studies to examine the
effects of Sp1 and NFnB family members on uroplakin Ib
reporter activity in TCC cell lines that do not normally ex-
press uroplakin Ib mRNA. Results similar to those in RT112
were obtained for the transfection of Sp1 alone, in 5637
cells (Figure 8A), and in J82, VMCub3, and TCCSuP cells
(Figure 8B). In contrast to RT112, transfection of NFnB pro-
teins was also able to cause modest enhancement (about
two-fold) of luciferase activity in J82, VMCub3, and TCCSuP
cells. However, the inclusion of Sp1 again resulted in fur-
ther elevation of reporter activity. In particular, the combina-
tion of Sp1 plus p65 plus c-Rel increased luciferase activity
(by 9.4-fold in 5637 cells, by 22-fold in VMCub3 cells, by 3.2-
fold in TCCSuP cells, and by 4.6-fold in J82 cells). Thus, en-
hanced transcriptional response to cotransfection of Sp1
with NFnB occurred in all cells, irrespective of their capacity
to express endogenous uroplakin Ib mRNA (Figure 2). These
data were consistent with our ideas that methylation of
the uroplakin Ib promoter inhibits transcription by blocking
the binding of Sp1 and NFnB to the promoter and also
Figure 6. Effect of site-directed mutagenesis (converting CG to TA at CpG2,
CpG3, and CpG4) on the transcriptional activity of the uroplakin Ib reporter
construct. (A) Mutagenesis of CpG2 had no effect on the transcriptional ac-
tivity of the uroplakin Ib promoter when the mutated construct was transfected
into TCC cell lines. (B) Mutagenesis of both CpG3 and CpG4 had no effect on
luciferase activity when transfected into TCC cells.
Figure 7. Effect on the transcriptional activity of site-directed mutagenesis of
a 6-bp sequence spanning either CpG3 or CpG. The sequence spanning
CpG3 or CpG4 was subjected to site-directed mutagenesis, and luciferase
reporter activity was assessed following transfection into RT112 or T24 cells.
Luciferase activity in RT112 cells was inhibited by approximately 30% by
mutation of either site, but there was no effect on low levels of luciferase
activity in T24 cells.
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suggested that expression of different NFnB family members
might play a role in determining normal levels of uroplakin
expression in different cell lines.
Discussion
This study has provided direct experimental evidence that
regulation of uroplakin Ib transcription is mediated by CpG
methylation at specific sites in the proximal promoter re-
gion. Transcriptional activation also requires the involvement
of both Sp1 (CpG3 and CpG4) and NFnB family proteins
(CpG3), which bind to the motifs encompassing these CpG
pairs. Methylation of CpG3 to CpG5 completely inhibits lu-
ciferase activity, suggesting that these sites are vital for
transcription from the reporter construct. Although CpG5 is
not part of a motif for Sp1 or NFnB binding, due to lack of
useful restriction sites, it is not technically possible to meth-
ylate only CpG3 and CpG4. Thus, we cannot currently rule
out the possibility that CpG5 might also be involved in
transcriptional regulation.
To verify that these CpG sites were functional in mediating
transcriptional activity, site-directed mutagenesis was car-
ried out by mutating CG to TA at both CpG3 and CpG4.
Surprisingly, these small mutations did not affect luciferase
activity, but a 6-bp mutation spanning either CpG3 or CpG4
reduced activity by about 30%, suggesting that methylation
of cytosine residue induces steric hindrance to transcription
factor binding. Because transcriptional activity was not com-
pletely inhibited, this result suggests that multiple sites in the
promoter have collaborative functions in inducing transcrip-
tional activity. Because methylation of CpG3 to CpG5 will
completely inhibit transcription, regulation of the transcrip-
tional activity of the reporter construct must reside in a
combination of these three sites. It is not yet clear if the
methylated CpGs directly inhibit the binding of transcription
factors or if methylated CpGs recruit methyl CpG–binding
proteins, which subsequently interfere with the binding of
transcription factors to the sites [24].
In our previous study [21], we identified several putative
transcription factor–binding motifs in the uroplakin Ib prox-
imal promoter, including Sp1 at CpG3 and CpG4, and a
putative NFnB site directly adjacent upstream of CpG3 (six
of nine matches for consensus NFnB). The current study
examined the ability of a double-stranded uroplakin Ib pro-
moter oligonucleotide containing these motifs to bind to
proteins in nuclear extracts from TCC cells and to recombi-
nant Sp1 and p50. Initial EMSA experiments demonstrated
that recombinant Sp1 and NFnB (p50) both bind to the
sequence, although we did not test if the other NFnB family
members can also bind to the oligonucleotide. When nuclear
Figure 8. Cotransfection of the uroplakin Ib reporter construct and plasmids constitutively expressing Sp1 or NFjB family proteins (p50, p65, or c-Rel). (A) (n)
RT112 cells; ( ) 5637 cells. (B) (n) J82 cells; ( )VMCub3 cells; (5) TCCSuP cells.
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extracts were subjected to EMSA analysis, complexes were
detected from cells expressing uroplakin Ib and showed
evidence for both Sp1 and NFnB binding to the oligonucle-
otide because consensus motif oligonucleotides were only
each partially able to inhibit complex formation.
The same complexes were also formed in nuclear extracts
prepared from cells that do not express endogenous uropla-
kin Ib mRNA and contain methylated CpG motifs in the
promoter [21]. These data suggest that lack of uroplakin Ib
expression in these cells is not due to the absence of rele-
vant transcription factors, but may be due to CpG methyla-
tion preventing transcription factor access to the motif. This
is also suggested by the fact that mutation of the CpGs in
the oligonucleotide did not affect factor binding because
there was still sufficient sequence remaining for the motif to
be recognized.
At least two patterns of transcription factor binding appear
to be present in nuclear extracts and may be a reflection
of the levels of reporter activity in their respective cells. In
HT1376 cells, binding of Sp1 only was detected and the
NFnB consensus oligo did not compete in binding to the 32P-
labeled oligonucleotide. Sp1 may potentially bind to either
CpG3 or CpG4 and complexes may be formed if Sp1 binds
to either possible motif; these would be of the same size.
Larger complexes would be formed if Sp1 binds simulta-
neously to both motifs; this pattern can be observed in
Figure 5A. In RT112 and SW1710 cells (Figure 5, B and C),
it appears that Sp1 and NFnB are both present in complexes
forming on this sequence because competition with either
consensus motif completely abrogates complex formation.
These data also suggest that both proteins are essential for
complex formation. Other examples of cooperative functions
for NFnB and Sp1 in gene activation have been reported in the
literature [25]. The cotransfection experiments discussed
above have provided further direct functional evidence that
both transcription factor families are required for an effective
transcription from the reporter construct. This correlates well
with the presence of consensus-binding sites for both Sp1 and
NFnB in the sequence encompassingCpG3and suggests that
this site might be the major regulatory motif in this sequence.
Interestingly, gel shift data using nuclear extracts from
RT112 and HT1376 cell lines also provided evidence for the
binding of an unknown protein to this region of the uroplakin
Ib promoter. Binding of this protein to either Sp1 or NFnB
was not competed with by oligos, suggesting that this pro-
tein binds independently of these latter two proteins. Con-
ceivably, this protein might function to facilitate functional
synergy between Sp1 and NFnB, although our transfection
data suggest that a third protein is not essential for the
cooperative activation of transcription by Sp1 and NFnB.
The current study demonstrated that cell lines that ex-
pressed significant levels of endogenous uroplakin Ib RNA
had the highest levels of transcriptional activity from the re-
porter construct. There was also very little activity supported
in non-urothelial lines, suggesting that this promoter se-
quence might be regulating the urothelial specificity of the
expression of uroplakin Ib. If control of urothelial specificity
resides in this sequence, this knowledge could be important
in allowing the design of tissue-specific vectors for gene
therapy approaches to treating TCC. Such an approach has
shown promise in studies using the uroplakin II promoter to
target urothelial tissue by an adenoviral vector. This vector
caused a significant regression of RT4 bladder cancer xeno-
grafts in mice [26]. However, other evidence suggests that
this strategy is likely to be less successful if the uroplakin Ib
promoter were used for gene therapy vectors, as expression
of uroplakin Ib is not strictly urothelial-specific. As an ex-
ample, the colorectal carcinoma cell line SW480 supports
moderate luciferase activity that is approximately half that
of the urothelial line HT1376 (Figure 2B). A large number of
non-urothelial uroplakin Ib expressed sequence tags have
also been identified, and the Unigene entry HS271580 (as of
May 9, 2005) currently reports 96 ESTs from tissues as
diverse as the eye, lung, brain, ovary, and pancreas, both in
purified islets and in pancreatic adenocarcinoma. Abundant
amounts of uroplakin Ib mRNA and protein have also been
detected in the corneal epithelium, although its function in
this context is not clear [27].
The sequence analyzed in the current study, although
vital for the positive regulation of the expression of uroplakin
Ib, is likely to be only partially responsible for the control of
endogenous uroplakin Ib mRNA expression. A recent study
from Olsburgh et al. [22] suggested that there were inhibitory
motifs directly upstream of the proximal promoter sequence
analyzed in our current study. In their study, Olsburgh et al.
identified a sequence at 628 bp, which was closely homol-
ogous to a putative TGF-b1 inhibitory element. The proximal
Figure 9. Proposed mechanisms regulating uroplakin Ib transcription from
specific CpG sites in the proximal promoter. (A) Binding of NFjB to CpG3
induces minimal levels of transcriptional activation. (B) Binding of Sp1 to
CpG3 and CpG4 allows low levels of transcription. (C) Both Sp1 and NFjB
family members binding to CpG3 and CpG4 can act in synergy to induce high
levels of transcription. High-level activity may also require the involvement of
another as-yet-identified factor binding to CpG3 and CpG4 and a factor bind-
ing to CpG5. (D) Methylation of CpG3, CpG4, and CpG5 prevents the binding
of Sp1 and NFjB, an unidentified factor, and a factor binding to CpG5, thus
blocking transcription.
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region analyzed in the current study is an activating region,
but control of levels of endogenous uroplakin Ib mRNA is
likely to be more complex.
In conclusion, our data demonstrate that transcriptional
activity of the uroplakin Ib reporter is regulated by CpGmeth-
ylation at CpG3, CpG4, and CpG5. Transcription is also
controlled by both Sp1 and NFnB family proteins, which bind
to their putative motifs encompassing CpG3 and CpG4 but
may also bind to an unidentified factor in this sequence and
to a factor binding to a sequence involving CpG5. As illus-
trated in Figure 9, Sp1, NFnB, and the unidentified factors
may be required to activate significant levels of transcription
from the luciferase reporter. However, if the reporter is meth-
ylated at CpG3, CpG4, and CpG5, binding of the factors may
be sterically hindered and transcriptionally blocked. Future
studies will determine if these factors are also important for
the regulation of uroplakin Ib expression in clinical samples
of TCC and will identify the molecular mechanisms by which
these tumors frequently lose expression of uroplakin Ib dur-
ing tumor progression.
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